 |
|||
|
RBM E-Newsletter [December 2011]The RBM E-Newsletter is a monthly publication of the Roll Back Malaria Partnership. Top story 21st RBM Board meeting
Highlights Princess Astrid of Belgium Visits Gulf Region
Partner spotlight RBM partner Novartis finds a new class of antimalarial drug candidates
What we're reading Science Magazine: Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery Center for Global Development: Brave New World The Huffington Post: The human cost of cutting global health funding USA Today: Neglected Diseases in Developing Nations - About the E-Newsletter The RBM E-Newsletter is a forum to share malaria news and resources. If you have a submission for the newsletter, please contact us. The E-Newsletter is produced by the Roll Back Malaria Partnership, which brings together more than 500 private and public sector partners to mobilize coordinated action against malaria worldwide.
|
New online resources RBM: The malaria program performance review (MPR)
Malaria Commodity Access: Procurement of Rapid Diagnostic Tests (RDTs) (in French) ..................................... Upcoming events 4-8 December 2011: ASTMH 60th Annual Meeting 13 December 2011: Launch of the WHO World Malaria Report 2011 9-13 January 2012: AMP English language scale-up and sustaining gains workshop 17-21 January 2012: AMP French language scale-up and sustaining gains workshop 25-29 January 2012: World Economic Forum Annual Meeting 2012 6-7 February 2012: 8th Malaria Advocacy Working Group meeting 6-6 February 2012: 7th VCWG annual meeting More events on the RBM Calendar ..................................... |
||
In a three-day meeting, hosted by the government of the People's Republic of China, the Board of the RBM Partnership discussed strategic priorities that will make the most pertinent contribution to achieving the targets and objectives of the Global Malaria Action Plan.
The Special Representative of the Roll Back Malaria Partnership, Her Royal Highness Princess Astrid of Belgium, has begun her visit of the Gulf region this week to advocate for stronger regional investment in global malaria control efforts.
Novartis and collaborators announced the discovery of a new dual-acting class of antimalarial compounds - the imidazolopiperazines (IZPs). 